checkAd

     143  0 Kommentare Akcea Therapeutics Announces New Appointments to its Board of Directors

    Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board

    BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the Akcea Board of Directors and Barbara Yanni as a new member of the board.  Both positions are effective immediately. Ms. Parshall has served as a member of Akcea’s Board of Directors since January 2015. She replaces Christopher Gabrieli, who will continue to serve as a board member.

    “On behalf of the Akcea Board and the entire Akcea team, we thank Chris for his leadership and dedicated service to Akcea during a period of many significant advancements including launching TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). Lynne has been an active board member who is very familiar with our business operations and goals and is the ideal candidate to guide our work as we plan for success in the years ahead,” said Damien McDevitt, Ph.D., interim chief executive officer at Akcea.

    Ms. Parshall is also currently a director and senior strategic advisor to Ionis Pharmaceuticals. She previously served as chief operating officer at Ionis from 1991-2018 where she was responsible for overseeing business operations in diverse areas including finance, legal, intellectual property, manufacturing, information technology, regulatory and alliance management, health and safety, corporate communications and business and corporate development. In addition, she participated in both development and research management committees.  Before joining Ionis, Ms. Parshall was a partner at Cooley LLP, where she represented several healthcare companies in a general practice specializing in corporate partnering and other technology-based transactions. She received her J.D. from Stanford Law School and her B.A. from Harvard College, and is a member of the American, California and San Diego bar associations. She also serves on the board of Cytokinetics, Inc. and is a member of the Licensing Executives Society.

    “As a member of the Akcea Board since its founding, I have an in-depth understanding of the Company’s business model and strong commercial and development capabilities. I also have a deep understanding of our products and the needs of the patient and clinician communities we serve. I am honored to accept this new role as chair of the Board and look forward to continuing to support the outstanding Akcea team as we plan for many new opportunities moving forward,” said Ms. Parshall.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Akcea Therapeutics Announces New Appointments to its Board of Directors Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea boardBOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) - Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the …